An ovarian cancer‐on‐a‐chip was used to test the targeting efficacy of Revacept, an anti‐GPVI monoclonal antibody, and its impact on platelets in the tumor.[85] The effect of targeting with Revacept, which targets GPVI in inhibiting proliferation and suppressing the invasions of ovarian cancer, was demonstrated using ovarian CoC that employed A2870 and OVCAR3 cancer cell lines.[85] These results agree with in vitro results found when treating colon cancer with Revacept.[317] However, Revacept has yet to be tested in vivo on animal models. Here, GP6 is linked to ovarian cancer.